Clinical trials: Follicular Lymphoma
Moderate or Severe Submental Fullness
Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01305577
- Testing
- Deoxycholic acid injection
- Where
- 30 sites in Belgium, France and 3 more
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Lymphoma
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures using radiolabeled monoclonal antibodies may improve the ability to detect and stage non-Hodgkin's lymphoma.
- Trial name
- NCT00003337
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1
PMCF Study Fortilink-TC Ti
This study is setup to be able to gather information on the safety and performance of the Fortilink-TC Ti cage of Paradigm Spine GmbH, up to one year after the surgery.
- Trial name
- NCT07834931
- Testing
- Transforaminal lumbar interbody fusion surgery
- Where
- 2 sites in Spain
- Volunteers
- 50 people
- Sponsor
- BAAT Medical Products B.V.
Follicular Lymphoma
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy.
- Trial name
- NCT07634471
- Testing
- MK-1045, Rituximab, Rituximab biosimilar
- Where
- 35 sites in United States, Argentina and 11 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Low-Grade
- Trial name
- NCT00060671
- Testing
- rituximab, Pixantrone (BBR 2778)
- Where
- 38 sites in United States
- Volunteers
- 800 people
- Sponsor
- CTI BioPharma
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of…
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Trial name
- CD20/19 CAR T (NCT06703892)
- Testing
- GF-CART01
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Relapsed or Refractory T-cell Lymphomas
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
- Trial name
- NCT06035497
- Testing
- BMS-986369
- Where
- 40 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
- Conditions
- T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
- Trial name
- NCT04234048
- Testing
- Fenretinide
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- SciTech Development, Inc.
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Rheumatoid Arthritis
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately…
- Trial name
- CREDO 4 (NCT03120949)
- Testing
- Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment
- Where
- 239 sites in United States, Argentina and 16 more
- Volunteers
- 2,106 people
- Sponsor
- R-Pharm International, LLC
Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate
PGx Medication Safety Reviews of Persons With IDD
The purpose of this study is to assess the feasibility of a comprehensive medication review and PGx initiative as part of the care process for individuals in the care of CP Unlimited.
- Conditions
- Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate, Developmental Disability
- Trial name
- NCT07092852
- Testing
- Cheek swab for PGx testing, Medication safety review
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- GalenusRx, Inc.
Diffuse Large B-Cell Lymphoma
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma.
- Trial name
- NCT07862764
- Volunteers
- 175 people
- Sponsor
- AbbVie
Lymphoma, Small Lymphocytic, Lymphoma
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
- Conditions
- Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
- Trial name
- REAL (NCT04342117)
- Testing
- duvelisib, PI3K inhibitor
- Where
- 11 sites in United States
- Volunteers
- 2 people
- Sponsor
- SecuraBio
Lymphoma, Non-Hodgkin
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade…
- Trial name
- NCT00933335
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured t…The goal of this Phase II single-arm, open-label clinical trial is to…
- Conditions
- Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT07713459
- Testing
- CART Infusion
- Volunteers
- 105 people
- Sponsor
- Kure Cells, INC
Cancer, Neoplasms
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
This is an open-label, multicenter, 2-part study to determine the recommended Phase 2 dose (RP2D) for GSK2816126 given twice weekly by intravenous (IV) infusion.
- Trial name
- NCT02082977
- Testing
- GSK2816126
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).
- Conditions
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, Mantle Zone Lymphoma Refractory/Recurrent
- Trial name
- NCT02981745
- Testing
- CT-1530
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Centaurus Biopharma Co., Ltd.
Lymphoma, Non-Hodgkin
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular…
- Trial name
- AUGMENT (NCT01938001)
- Testing
- Rituximab, Lenalidomide
- Where
- 160 sites in United States, Belgium and 15 more
- Volunteers
- 358 people
- Sponsor
- Celgene
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
- Trial name
- NCT00807495
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Obesity, Mild
Safety & Effectiveness of TENS Weight Management Compared to a Sham
This is a multicenter, randomized, blinded, parallel group, controlled study intended to evaluate the safety and effectiveness of treating overweight and Class 1 obese patients with the Elira System (TENS active treatment)…
- Trial name
- NCT05675384
- Testing
- TENS Active Treatment
- Where
- 6 sites in United States
- Volunteers
- 395 people
- Sponsor
- Elira, Inc.